Research on mechanisms in chemical carcinogenesis often requires authentic monomeric carcinogen-DNA adducts. Few adducts are commercially available, and individuals often obtain submilligram levels of adducts from carcinogen-treated DNA; this may be insufficient for their needs. The objective of this project is to determine the feasibility of developing generic approaches to gram-scale synthesis of carcinogen-DNA adducts that may be used in modern molecular toxicology studies as postlabeling or chromatography standards, in developing immunoassays, or for incorporation into oligonucleotides. This project will specifically address preparation of 3'-monophosphates of major adducts of dG and dA with 7-bromomethyl-12-methylbenzanthracene (BMBA) or benzo(a)pyrene diol-epoxide I (BPDE), as standards for the 32p-postlabeling assay. Silylation versus acylation will be evaluated for transient protection of BPDE and deoxyribose bydroxyls; their stability during phosphorylation and ease of selective removal will be checked. 0-silylated or -acylated amines (from ammoniation of BPDE or BMBA) will be condensed with the appropriate protected halopurine nucleoside to yield fully blocked N2-dG or N 6-dA derivatives. Phosphorylation will follow selective removal of the 3'-protecting group.
Anticipated Results:This research will lead to the commercial availability of various carcinogen-DNA adducts. These will be marketed as chromatography standards, as precursors for adducted oligonucleotide synthesis, as postlabeling standards, or as haptens for antibody assays. Commercially available monomeric carcinogen-DNA adducts will facilitate chemical carcinogenesis research.National Cancer Institute
